卡培他滨单药一线治疗晚期老年胃癌临床观察  

Clinical Observation of Capecitabine as first-line treatment in elderly patients with advanced gastric cancer

作　　者：彭平[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤中心,湖北武汉430030

出　　处：《中华肿瘤防治杂志》2015年第B11期129-130,共2页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的探讨卡培他滨一线化疗治疗晚期老年胃癌的近期疗效和安全性。方法收集我院2009-04-2014-05接受卡培他滨单药化疗的晚期老年胃癌患者87例作为研究对象。卡培他滨1000mg／m2，口服，2a／d，持续2周，休息1周，21d为1个周期。连用3个周期后评价疗效。结果87例患者治疗的有效率为12．6％，疾病控制率为51．7％。治疗3个周期后的主要不良反应为中性粒细胞下降、胃肠道不适、手足综合征、恶心、呕吐和口腔炎，均可耐受。结论卡培他滨单药一线治疗晚期老年胃癌安全有效，值得临床推广应用。OBJECTIVE To evaluate the efficacy and adverse effect of capecitabine as first-line chemotherapy in eld- erly patients with advanced gastric cancer. METHODS Eight-seven elderly patients with advanced gastric cancer were collected from Apr. 2009 to May 2014. All patients received capecitabine 1 000 mg/m2 , bid. The treatment lasted for 14 days followed by one week rest period, the cycle was repeated every three weeks. Assessment of the response was made after three cycles. RESULTS The disease control rate was 51. 7% and the overall objective response rate was 12.6% in the capecitabine group. The major adverse effect in the capecitabine group included leucocytopenia, digestive toxic reactions, hand and foot syndrome, nause, vomiting and stomatitis. CONCLUSION eapecitabine offers an effective, safe and well-tolerated regimen for e elderly patients with gastric cancer.

关 键 词：胃肿瘤 老年患者 卡培他滨 

分 类 号：R735.2[医药卫生—肿瘤]